$ARAY

Accuray Inc. amended a major shareholder report, detailing a $55M issuance of Series A Convertible Preferred Stock to investors, including affiliates of the reporting person. The deal involves $15M in cash and $40M in debt conversion, with warrants issued as incentives. The transaction is subject to closing conditions and stockholder approval. If not approved, a $15M fee is payable. The Series A Preferred Stock is convertible into common stock at $0.50 per share. TCW Asset Management gains board

Accuray (ARAY) reported a 21% revenue decline to $100.9M in Q4 2026, with China's market contributing to a 42% drop in product revenue. The company secured $60M in financing from TCW Asset Management, improving its balance sheet. Service revenue grew 6%, and cost savings exceeded targets. However, Accuray did not provide 2027 guidance due to trade policy uncertainties.

Accuray (ARAY) reported Q4 2026 revenue of $100.9M, down 21% YoY, with product revenue declining 42% due to geopolitical tensions. Service revenue grew 6% to $60.1M. Full-year revenue was $401.9M, down 12%. The company realized $20M in cost savings and expects $15M more in FY27. Adjusted EBITDA was $12.9M, up from $9.4M YoY. Management cited trade policy uncertainty and regional volatility as risks.

Accuray Incorporated reported Q4 2026 earnings, noting a $58M revenue decline due to China's geopolitical tensions. The company is shifting to a partner-centric model and saw 6% service revenue growth. Management highlighted clinical data validating their technology and $20M in cost improvements. No formal guidance was given for 2027 due to uncertainty. A debt-to-equity conversion with TCW and a reverse stock split plan were announced.

Accuray Inc (ARAY) reported a 12% year-over-year revenue decline to $402M for fiscal 2026, with product revenue down 27% due to China sales drop. Gross margin fell to 27.7% from 32.1%, and operating loss was $26.4M. Management cited geopolitical tensions and tariff uncertainty. The company secured $55M in funding from TCW Asset Management, converting debt and receiving cash investment. Service revenue grew 4% year-over-year, and the company aims to improve cost structure and market reach in fisc

Accuray (ARAY) reported Q4 and fiscal 2026 results, with total revenue down 21% YoY to $100.9M. Service revenue rose 6% YoY, while product revenue fell 42%. The company exceeded cost-saving targets, secured financing, and plans growth in service revenue for fiscal 2027.

ACCURAY INC (ARAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results MADISON, Wisconsin, August 19, 2026 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026 , ended June 30, 2026 . Key Highlights ● The Company’s t

Accuray Incorporated (NASDAQ: ARAY) said it appointed Todd Brown to lead a newly created Enterprise Performance Optimization organization and named Sofiane Laoussadi as Senior VP, Global Services & Solutions. The company links the hires to its Transformation Phase II plan to improve execution, lower costs, and boost customer value. Accuray said services generated 57% of fiscal 2026 net revenues.

Samsung Electronics’ Medical Device Business Division and Samsung Medison said they are expanding partnerships beyond diagnostic imaging. They signed a non-binding LOI with U.S. radiosurgery specialist Accuray to explore integrating Samsung’s mobile CT (BodyTom) with Accuray’s CyberKnife for volumetric imaging-based precision radiation therapy. Samsung also referenced an expanded collaboration with HistoSonics.

Accuray Inc. (NASDAQ: ARAY) said it reached definitive agreements with its primary lender and largest shareholder, TCW Asset Management, to delever $40 million via convertible preferred stock, add $15 million equity investment, and potentially access a delayed draw term loan up to $5 million. The plan includes covenant waivers through Dec. 31, 2027, board changes, and a reverse stock split. Accuray also outlined non-binding LOIs with Samsung HME America and RaySearch, plus expanded work with Tat